(Q37857737)

24 August 2017

1 reference

title

Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians (English)

1 reference

24 August 2017

1 reference

Hitoshi Yokoyama

1

1 reference

24 August 2017

Hiroshi Okuyama

series ordinal

2

1 reference

24 August 2017

Hideki Yamaya

series ordinal

3

1 reference

24 August 2017

publication date

25 March 2011

1 reference

Clinical and experimental nephrology

24 August 2017

published in

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

321-330

1 reference

Demographic differences in the development of lupus nephritis: a retrospective analysis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Severe lupus nephritis: racial differences in presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

An epidemiologic analysis of end-stage lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

An overview of regular dialysis treatment in Japan (as of 31 December 2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Pathogenetic features of severe segmental lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

The pathology of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0434-0

The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide

21 January 2018

1 reference

12 December 2020

Glomerular podocytopathy in patients with systemic lupus erythematosus

1 reference

12 December 2020

Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins

1 reference

12 December 2020

Inflammation: Rituximab in ANCA vasculitis and lupus: bittersweet results

1 reference

12 December 2020

The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment

1 reference

12 December 2020

Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study

1 reference

12 December 2020

Relationship between initial diagnosis and long-term prognosis in lupus nephritis

1 reference

12 December 2020

Long-term outcome of Chinese patients with membranous lupus nephropathy

1 reference

12 December 2020

Collapsing glomerulopathy

1 reference

12 December 2020

Tacrolimus is effective for lupus nephritis patients with persistent proteinuria.

1 reference

12 December 2020

1 reference

12 December 2020

Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

New insight into nephrotic lupus glomerulonephritis

1 reference

12 December 2020

Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications

1 reference

12 December 2020

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

12 December 2020

10.1007/S10157-011-0434-0

Identifiers

DOI

1 reference

24 August 2017

1 reference